222 related articles for article (PubMed ID: 28554757)
1. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
Kim NY; Pyo JS
Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
[TBL] [Abstract][Full Text] [Related]
3. Analysis of MAT3 gene expression in NSCLC.
Zheng S; Du Y; Chu H; Chen X; Li P; Wang Y; Ma Y; Wang H; Zang W; Zhang G; Zhao G
Diagn Pathol; 2013 Oct; 8():166. PubMed ID: 24107548
[TBL] [Abstract][Full Text] [Related]
4. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
Xu XY; Lin N; Li YM; Zhi C; Shen H
Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
6. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
[TBL] [Abstract][Full Text] [Related]
7. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
Wang X; Du Z; Li L; Shi M; Yu Y
Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
[TBL] [Abstract][Full Text] [Related]
8. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
[TBL] [Abstract][Full Text] [Related]
9. Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.
Zhan P; Shen XK; Qian Q; Wang Q; Zhu JP; Zhang Y; Xie HY; Xu CH; Hao KK; Hu W; Xia N; Lu GJ; Yu LK
Oncol Rep; 2012 Apr; 27(4):1072-8. PubMed ID: 22200856
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
11. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
12. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.
Anagnostou VK; Lowery FJ; Zolota V; Tzelepi V; Gopinath A; Liceaga C; Panagopoulos N; Frangia K; Tanoue L; Boffa D; Gettinger S; Detterbeck F; Homer RJ; Dougenis D; Rimm DL; Syrigos KN
BMC Cancer; 2010 May; 10():186. PubMed ID: 20459695
[TBL] [Abstract][Full Text] [Related]
13. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer.
Noh SJ; Baek HA; Park HS; Jang KY; Moon WS; Kang MJ; Lee DG; Kim MH; Lee JH; Chung MJ
Pathol Res Pract; 2013 Jun; 209(6):365-70. PubMed ID: 23702379
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
Zhao S; Qiu Z; He J; Li L; Li W
Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M
Tumori; 2014; 100(1):60-8. PubMed ID: 24675493
[TBL] [Abstract][Full Text] [Related]
18. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
